News
Rituximab maintenance has a durable benefit in follicular lymphoma
- Author:
- Susan London
At a median of 9 years of follow-up, progression-free survival was extended versus observation but there was no difference in overall survival.
News
Gene signature may help guide initial CLL treatment choice
- Author:
- Susan London
A 17-gene expression signature may help predict which patients with IGHV-unmutated disease will benefit from frontline FCR chemoimmunotherapy or...
News
Use and costs of CRC end-of-life care differ sharply between U.S., Canada
- Author:
- Susan London
On average, mean total costs of health care resources in the last month of life were 25% higher for SEER-Medicare patients compared with Ontario...
News
Sunitinib for mRCC: Real-world experience differs somewhat
- Author:
- Susan London
A cohort study finds that patients treated with sunitinib as first-line therapy in routine clinical practice had poorer overall survival but also...
News
Training, alerts up the odds of discussions about genomic testing costs
- Author:
- Susan London
A variety of physician and practice factors – some of them modifiable – increased the likelihood that oncologists discussed these often expensive...
News
Ezrin negativity predicts poor prognosis in clear cell RCC
- Author:
- Susan London
Lack of this cytoskeleton linker protein was associated with adverse prognostic factors and independently predicted poorer disease-specific...
News
Stereotactic body radiation therapy safe, effective for moderately central NSCLC
- Author:
- Susan London
A stereotactic body radiation therapy regimen of 50 Gy given in five fractions had limited toxicity and yielded good survival in a cohort of...
News
Lazertinib has good showing in EGFR-mutated advanced NSCLC
- Author:
- Susan London
Data for 127 patients treated at various doses showed that 54% had a response to the new third-generation EGFR TKI. Moreover, 44% of those with...
News
Immunotherapy enables nephrectomy with good outcomes in advanced RCC
- Author:
- Susan London
Patients able to undergo nephrectomy after receiving immune checkpoint inhibitors had favorable surgical outcomes and pathologic responses in the...
News
Nivolumab-ipilimumab nets long-term survival in advanced melanoma
- Author:
- Susan London
An update of CheckMate 067 finds that with combination nivolumab and ipilimumab therapy, 52% of patients were alive at 5 years, and the large...
News
Cancer burden: Multiple metrics needed to clarify the big picture
- Author:
- Susan London
A cancer’s so-called epidemiologic signature – the composite pattern of incidence, mortality, and metastatic incidence – helps sort out the...
News
AF risk is elevated after early-stage breast cancer diagnosis
- Author:
- Susan London
The rate of AF was elevated in the first year post diagnosis and after 5 years post diagnosis, with greater elevation for women who received...
News
Mortality after breast cancer diagnosis found higher for men
- Author:
- Susan London
Male patients had 19% higher 5-year mortality than their female counterparts even after confounders were taken into account.
News
ASCT may cure follicular lymphoma for some rituximab-naive patients
- Author:
- Susan London
A retrospective cohort study suggests that ASCT, if performed promptly, can be curative in patients who have had an early failure of first-line...
News
Meta-analysis supports hormone therapy-targeted therapy combo for advanced breast cancer
- Author:
- Susan London
A meta-analysis of 140 trials indicated that combining hormone therapy with targeted therapy led to significantly better efficacy, reducing the...